VERTEX PHARMACEUTICALS INC / MA (VRTX)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 1.5B 3B 4.5B Q3 '21: 2B Q4 '21: 2.1B Q1 '22: 2.1B Q2 '22: 2.2B Q3 '22: 2.3B Q4 '22: 2.3B Q1 '23: 2.4B Q2 '23: 2.5B Q3 '23: 2.5B Q4 '23: 2.5B Q1 '24: 2.7B Q2 '24: 2.6B Q3 '24: 2.8B Q4 '24: 2.9B Q1 '25: 2.8B Q2 '25: 3B Q3 '25: 3.1B Q4 '25: 3.2B Q1 '26: 3B Q2 '26: 3.3B Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income Quarterly

-4.5B -3B -1.5B 0 1.5B 3B 4.5B Q3 '21: 1.1B Q4 '21: 877.7M Q1 '22: 1B Q2 '22: 1.1B Q3 '22: 1.1B Q4 '22: 1B Q1 '23: 779M Q2 '23: 1B Q3 '23: 1B Q4 '23: 988.5M Q1 '24: 1.1B Q2 '24: -3.5B Q3 '24: 1.1B Q4 '24: 1B Q1 '25: 630.1M Q2 '25: 1.2B Q3 '25: 1.2B Q4 '25: 1.2B Q1 '26: 1.1B Q2 '26: 1.2B Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-4.5B -3B -1.5B 0 1.5B 3B 4.5B Q3 '21: 851.9M Q4 '21: 770.1M Q1 '22: 762.1M Q2 '22: 810.5M Q3 '22: 930.5M Q4 '22: 818.9M Q1 '23: 699.8M Q2 '23: 915.7M Q3 '23: 1B Q4 '23: 968.8M Q1 '24: 1.1B Q2 '24: -3.6B Q3 '24: 1B Q4 '24: 913M Q1 '25: 646.3M Q2 '25: 1B Q3 '25: 1.1B Q4 '25: 1.2B Q1 '26: 1B Q2 '26: 1.1B Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue Quarterly

0 200M 400M 600M Q3 '21: 236.5M Q4 '21: 247.4M Q1 '22: 245.8M Q2 '22: 261.8M Q3 '22: 289.4M Q4 '22: 283.3M Q1 '23: 266.9M Q2 '23: 308.6M Q3 '23: 318.7M Q4 '23: 368M Q1 '24: 342.6M Q2 '24: 371.9M Q3 '24: 392.6M Q4 '24: 423.4M Q1 '25: 363M Q2 '25: 407.5M Q3 '25: 414.8M Q4 '25: 466M Q1 '26: 392.8M Q2 '26: 489.2M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Cash Flow Quarterly

-4.5B -3B -1.5B 0 1.5B 3B 4.5B Q3 '21: 927.2M Q4 '21: 995M Q1 '22: 956.2M Q2 '22: 1.1B Q3 '22: 955.5M Q4 '22: 1.1B Q1 '23: 899.9M Q2 '23: 1.1B Q3 '23: 1.3B Q4 '23: 234.6M Q1 '24: 1.3B Q2 '24: -3.8B Q3 '24: 1.4B Q4 '24: 584.6M Q1 '25: 818.9M Q2 '25: 1.1B Q3 '25: 1.2B Q4 '25: 498M Q1 '26: 1.4B Q2 '26: 1.1B Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

-4.5B -3B -1.5B 0 1.5B 3B 4.5B Q3 '21: 874.8M Q4 '21: 933.2M Q1 '22: 892.6M Q2 '22: 1.1B Q3 '22: 901.3M Q4 '22: 1B Q1 '23: 857.8M Q2 '23: 1.1B Q3 '23: 1.2B Q4 '23: 176.5M Q1 '24: 1.2B Q2 '24: -3.8B Q3 '24: 1.3B Q4 '24: 492M Q1 '25: 778.2M Q2 '25: 927.4M Q3 '25: 1.1B Q4 '25: 348.6M Q1 '26: 1.3B Q2 '26: 1B Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 90M 180M 270M Q2 '20: 263.4M Q3 '20: 264.1M Q4 '20: 263.1M Q1 '21: 261.9M Q2 '21: 261M Q3 '21: 259.7M Q1 '22: 257.9M Q2 '22: 258.7M Q3 '22: 259.5M Q1 '23: 260.3M Q2 '23: 260.4M Q3 '23: 260.6M Q1 '24: 261.1M Q2 '24: 258.1M Q3 '24: 261M Q1 '25: 259.5M Q2 '25: 258.9M Q3 '25: 257.6M Q1 '26: 256.3M Q2 '26: 255.2M Q3 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-6.00 0.00 6.00 12.00 18.00 Q3 '21: 8.33 Q4 '21: 9.01 Q1 '22: 9.48 Q2 '22: 12.35 Q3 '22: 12.66 Q4 '22: 12.82 Q1 '23: 12.55 Q2 '23: 12.94 Q3 '23: 13.32 Q4 '23: 13.89 Q1 '24: 15.41 Q2 '24: -2.03 Q3 '24: -1.99 Q4 '24: -2.08 Q1 '25: -3.80 Q2 '25: 14.11 Q3 '25: 14.30 Q4 '25: 15.32 Q1 '26: 16.85 Q2 '26: 17.17 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.